Table 3 Anti-HEV IgG seropositivity among participants who were seropositive at baseline
Serum collection timepoint (month) | Single-dose group % (n/N) | Two-dose group (the 0–1-month schedule) % (n/N) | Two-dose group (the 0–6-month schedule) % (n/N) | Three-dose group % (n/N) | Placebo group % (n/N) |
|---|---|---|---|---|---|
Anfeng | |||||
 0 | 100.0 (28/28) | 100.0 (62/62) | 100.0 (73/73) | 100.0 (1989/1989) | 100.0 (2123/2123) |
 7 | 96.4 (27/28) | 98.4 (61/62) | 100.0 (73/73) | 99.9 (1988/1989) | 96.9 (2057/2123) |
 19 | 95.8 (23/24) | 97.8 (45/46) | 100.0 (54/54) | 99.9 (1726/1728) | 97.4 (1755/1801) |
 31 | 94.1 (16/17) | 100.0 (42/42) | 100.0 (50/50) | 99.8 (1550/1553) | 95.7 (1528/1597) |
 43 | 94.7 (18/19) | 95.6 (43/45) | 100.0 (45/45) | 99.7 (1554/1559) | 89.9 (1453/1617) |
 67 | 100.0 (15/15) | 97.2 (35/36) | 100.0 (46/46) | 99.7 (1465/1470) | 82.4 (1254/1522) |
 91 | 100.0 (14/14) | 94.1 (32/34) | 95.6 (43/45) | 97.9 (1409/1439) | 81.9 (1258/1536) |
Qindong | |||||
 0 | 100.0 (10/10) | 100.0 (17/17) | 100.0 (19/19) | 100.0 (670/670) | 100.0 (710/710) |
 7 | 100.0 (10/10) | 100.0 (17/17) | 100.0 (19/19) | 100.0 (670/670) | 99.0 (703/710) |
 13 | 100.0 (8/8) | 100.0 (16/16) | 100.0 (14/14) | 100.0 (618/618) | 98.3 (629/640) |
 19 | 100.0 (1/1) | NA | 100.0 (3/3) | 100.0 (75/75) | 95.2 (79/83) |
 31 | 100.0 (6/6) | 100.0 (12/12) | 100.0 (14/14) | 99.8 (524/525) | 94.9 (538/567) |
 43 | 100.0 (6/6) | 100.0 (10/10) | 100.0 (16/16) | 99.6 (505/507) | 96.3 (517/537) |
 55 | 100.0 (8/8) | 100.0 (10/10) | 100.0 (15/15) | 99.8 (504/505) | 89.1 (466/523) |
 79 | 100.0 (8/8) | 88.9 (8/9) | 100.0 (13/13) | 99.0 (492/497) | 90.6 (493/544) |
 103 | 100.0 (6/6) | 100.0 (11/11) | 100.0 (12/12) | 100.0 (471/471) | 89.4 (470/526) |
